Live Breaking News & Updates on Kinase Inhibitor

Stay updated with breaking news from Kinase inhibitor. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Foghorn Therapeutics Provides First Quarter 2024 Financial and Corporate Update

Dose escalation in FHD-286 combination trial in AML continues to progress with clinical data expected in the second half of 2024; potential to be a first-in-class oral broad-based differentiation. ....

United States , United Kingdom , Peter Kelleher , Greg Dearborn , Adam Silverstein , Karin Hellsvik , Adrian Gottschalk , B Degrader Program , Key Recent Program Updates , American Association For Cancer Research , Exchange Commission , Degrader Program , Therapeutics Inc , Foghorn Therapeutics Inc , Development Expenses , Company Annual Report On Form , Gene Traffic Control , Chief Executive Officer , Cancer Research , Annual Meeting , Chromatin Regulation , Chromatin Regulation Summit , Kristian Humer , Chief Financial , Recent Program Updates , Kinase Inhibitor ,

HUTCHMED Announces Savolitinib sNDA Accepted in China for Treatment-Naïve or Previously Treated ...

— Oral presentation at the European Lung Cancer Congress 2024 of Phase IIIb data demonstrating median PFS of 13.7 months and median OS not reached in treatment-naïve patients — ....

Hong Kong , United States , Atholl Tweedie , Zhou Yi , Ben Atwell , Single Institution Study , American Cancer Society , Stock Exchange Of Hong Kong , China National Medical Products Administration , Exchange Commission , European Lung Cancer Congress On , European Lung Cancer Congress , National Reimbursement Drug List , World Health Organization , China Limited , International Agency For Research On Cancer , New Drug Application , Lung Cancer , Securities Litigation Reform Act , Stock Exchange , Hong Kong Limited , International Agency , Accessed November , Clinical Oncology Provisional Opinion , Epidermal Growth Factor Receptor , Mutation Testing ,

HUTCHMED Announces Savolitinib sNDA Accepted in China for Treatment-Naïve or Previously Treated Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC

Oral presentation at the European Lung Cancer Congress 2024 of Phase IIIb data demonstrating median PFS of 13.7 months and median OS not reached in treatment-naïve patients If. ....

Hong Kong , United States , Ben Atwell , Zhou Yi , Atholl Tweedie , China Limited , European Lung Cancer Congress On , American Cancer Society , National Reimbursement Drug List , Stock Exchange Of Hong Kong , European Lung Cancer Congress , International Agency For Research On Cancer , World Health Organization , Exchange Commission , Single Institution Study , China National Medical Products Administration , New Drug Application , Lung Cancer , Securities Litigation Reform Act , Stock Exchange , Hong Kong Limited , International Agency , Clinical Oncology Provisional Opinion , Epidermal Growth Factor Receptor , Mutation Testing , Kinase Inhibitor ,

TAGRISSO® (osimertinib) demonstrated overwhelming efficacy benefit for patients with unresectable, Stage III EGFR-mutated lung cancer in LAURA Phase III trial

First EGFR inhibitor and targeted treatment to demonstrate progression-free survival benefit in Stage III setting

. ....

United States , United Kingdom , Suresh Ramalingam , Susan Galbraith , Cerner Cancermpact , Daiichi Sankyo , International Agency For Research On Cancer , American Cancer Society , Lung Ambition Alliance , Winship Cancer Institute Of Emory University , Lungevity Foundation , Single Institution Study , World Health Organisation , Executive Director , Winship Cancer Institute , Emory University , Executive Vice President , Prescription Information , Patient Information , South America , Rare Diseases , International Agency , Lung Fact , Accessed February , What Is Lung , Clinical Oncology Provisional Opinion ,

AstraZeneca's Tagrisso plus chemotherapy appoved for lung cancer in the US

AstraZeneca's Tagrisso approved in the US for EGFRm non-small cell lung cancer with chemotherapy. FLAURA2 trial results show significant benefit. ....

United States , Dave Fredrickson , Laurie Ambrose , American Cancer Society , Pathology Lab , Drug Administration , Dana Farber Cancer Institute , National Comprehensive Cancer Network , Lungevity Foundation , National Comprehensive Cancer Network Inc , Priority Review , New England Journal , Executive Vice President , Oncology Business Unit , Lung Cancer , Practical Guidelines , Project Orbis , Non Small Cell , Accessed February , What Is Lung , Cancer Biomarkers , Present Status , Clinical Oncology Provisional Opinion , Epidermal Growth Factor Receptor , Mutation Testing , Kinase Inhibitor ,